Study Evaluating the Prognostic and Predictive Value of Response to First-Line Chemotherapy by Detection of Circulating Tumor Cells (CTC) in Patients With Metastatic Breast Cancer
- Predict the overall and progression-free survival of patients with stage IV breast
cancer by measuring the rate of circulating tumor cells (CTC) before the second course
- Predict overall and progression-free survival of these patients by measuring the rate
of CTC before the start of chemotherapy, at the first tumor evaluation, and after 2-3
courses of chemotherapy.
- Correlate the detection of CTC with tumor markers, clinical response, and radiological
- Study the changing status of HER-2 in CTC in patients receiving trastuzmab
OUTLINE: This is a multicenter study.
Blood samples are collected at baseline, before the second course of chemotherapy, before
the third or fourth course of chemotherapy, and when progressive disease is diagnosed
(before second-line treatment is initiated). Circulating tumor cells from the blood samples
are examined by immunofluorescence.
Patients are followed periodically for up to 3 months.
Correlation of circulating tumor cells (CTC) with overall survival
Jean-Yves Pierga, MD, PhD
United States: Federal Government